This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetic Disorders  • Anemias  • Hematology, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2008;299(4):395-396.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—Despite progress in recent years in the diagnosis and treatment of sickle cell disease and thalassemia, significant improvements are still needed in providing adequate care. That was the consensus of various researchers who presented new study data pertaining to these blood disorders at the 49th Annual Meeting of the American Society of Hematology held here in December.

Progress is being made in the treatment of sickle cell disease, but more work remains. (Photo credit: Eye of Science/www.sciencesource.com)

"As physicians, we need to better understand how to treat . . . patients from childhood through their adult life," said Marilyn Telen, MD, the Division Chief of Hematology at Duke University in Durham, NC. "Further, by understanding how to effectively mitigate the [adverse] consequences of [treatment], we can better serve a broad range of patients who suffer from red blood cell disorders," she added.

IRONING OUT CHELATION

Investigators from the United States and . . . [Full Text of this Article]